REGNÂ – Regeneron Pharmaceuticals, Inc.
Float Short %
2.24
Margin Of Safety %
-2
Put/Call OI Ratio
0.77
EPS Next Q Diff
-1.6
EPS Last/This Y
-1.48
EPS This/Next Y
-3.3
Price
589.35
Target Price
728.27
Analyst Recom
1.64
Performance Q
-1.23
Relative Volume
1.23
Beta
0.34
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | REGN | 563.22 | 0.76 | 0.57 | 45334 |
| 2025-07-28 | REGN | 558.62 | 0.75 | 1.56 | 44483 |
| 2025-07-29 | REGN | 557.93 | 0.77 | 0.99 | 45278 |
| 2025-07-30 | REGN | 554.81 | 0.78 | 0.25 | 45850 |
| 2025-07-31 | REGN | 545.4 | 0.77 | 0.51 | 46138 |
| 2025-08-01 | REGN | 559.71 | 0.74 | 0.65 | 50255 |
| 2025-08-04 | REGN | 571.76 | 0.74 | 0.87 | 45690 |
| 2025-08-05 | REGN | 569.98 | 0.73 | 0.48 | 45729 |
| 2025-08-06 | REGN | 555.08 | 0.73 | 0.45 | 45878 |
| 2025-08-07 | REGN | 560.19 | 0.73 | 0.58 | 46173 |
| 2025-08-08 | REGN | 563.06 | 0.73 | 1.28 | 46336 |
| 2025-08-11 | REGN | 545.87 | 0.72 | 0.42 | 44721 |
| 2025-08-12 | REGN | 556.45 | 0.72 | 0.43 | 45340 |
| 2025-08-13 | REGN | 561.55 | 0.72 | 0.45 | 45667 |
| 2025-08-14 | REGN | 565.9 | 0.72 | 1.34 | 45656 |
| 2025-08-15 | REGN | 580.39 | 0.74 | 0.73 | 46391 |
| 2025-08-18 | REGN | 574.05 | 0.78 | 0.83 | 40242 |
| 2025-08-19 | REGN | 571.45 | 0.78 | 1.16 | 42228 |
| 2025-08-20 | REGN | 591.34 | 0.80 | 1.12 | 42723 |
| 2025-08-21 | REGN | 598.25 | 0.77 | 0.78 | 43844 |
| 2025-08-22 | REGN | 589.55 | 0.77 | 0.88 | 44218 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | REGN | 563.10 | -27.2 | -1189.6 | 35.35 |
| 2025-07-28 | REGN | 558.70 | -27.0 | -1211.2 | 35.44 |
| 2025-07-29 | REGN | 558.15 | -27.0 | -1181.7 | 35.44 |
| 2025-07-30 | REGN | 554.58 | -27.1 | -1205.1 | 35.44 |
| 2025-07-31 | REGN | 545.46 | -27.1 | -1248.0 | 35.44 |
| 2025-08-01 | REGN | 558.87 | -27.1 | -1073.2 | 35.44 |
| 2025-08-04 | REGN | 571.54 | -23.8 | -1083.0 | 37.80 |
| 2025-08-05 | REGN | 569.90 | -23.8 | -1190.0 | 37.80 |
| 2025-08-06 | REGN | 555.06 | -22.7 | -1237.3 | 39.26 |
| 2025-08-07 | REGN | 559.80 | -22.7 | -1095.8 | 39.26 |
| 2025-08-08 | REGN | 563.00 | -22.7 | -1106.9 | 39.26 |
| 2025-08-11 | REGN | 546.14 | -22.7 | -1253.5 | 39.26 |
| 2025-08-12 | REGN | 556.35 | -22.5 | -1051.8 | 39.47 |
| 2025-08-13 | REGN | 561.55 | -22.5 | -1093.5 | 39.47 |
| 2025-08-14 | REGN | 565.83 | -22.5 | -1099.1 | 39.47 |
| 2025-08-15 | REGN | 580.37 | -22.5 | -1025.9 | 39.43 |
| 2025-08-18 | REGN | 573.93 | -22.4 | -1176.2 | 39.43 |
| 2025-08-19 | REGN | 571.78 | -22.4 | -1145.6 | 39.42 |
| 2025-08-20 | REGN | 591.16 | -22.4 | -991.3 | 39.42 |
| 2025-08-21 | REGN | 598.30 | -22.4 | -1079.9 | 39.42 |
| 2025-08-22 | REGN | 589.35 | -22.4 | -1190.6 | 39.42 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | REGN | 0.00 | 1.05 | 1.99 |
| 2025-07-28 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-29 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-30 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-07-31 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-08-01 | REGN | 0.00 | -0.30 | 1.99 |
| 2025-08-04 | REGN | 0.00 | -0.46 | 1.99 |
| 2025-08-05 | REGN | 0.00 | -0.46 | 1.99 |
| 2025-08-06 | REGN | 0.00 | -0.46 | 1.99 |
| 2025-08-07 | REGN | 0.00 | -0.46 | 2.03 |
| 2025-08-08 | REGN | 0.00 | -0.46 | 2.03 |
| 2025-08-11 | REGN | 0.00 | -0.47 | 2.03 |
| 2025-08-12 | REGN | 0.00 | -0.47 | 2.24 |
| 2025-08-13 | REGN | 0.00 | -0.47 | 2.24 |
| 2025-08-14 | REGN | 0.00 | -0.47 | 2.24 |
| 2025-08-15 | REGN | 0.00 | -0.47 | 2.24 |
| 2025-08-18 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-19 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-20 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-21 | REGN | 0.00 | -5.59 | 2.24 |
| 2025-08-22 | REGN | 0.00 | -5.59 | 2.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
10.72
Avg. EPS Est. Current Quarter
9.67
Avg. EPS Est. Next Quarter
9.12
Insider Transactions
Institutional Transactions
-5.59
Beta
0.34
Average Sales Estimate Current Quarter
3571
Average Sales Estimate Next Quarter
3610
Fair Value
577.1
Quality Score
99
Growth Score
71
Sentiment Score
92
Actual DrawDown %
51.3
Max Drawdown 5-Year %
-59.7
Target Price
728.27
P/E
14.85
Forward P/E
14.56
PEG
14.42
P/S
4.4
P/B
2.09
P/Free Cash Flow
16.21
EPS
39.69
Average EPS Est. Cur. Y​
39.42
EPS Next Y. (Est.)
36.12
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.37
Relative Volume
1.23
Return on Equity vs Sector %
-9.8
Return on Equity vs Industry %
3.1
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
3.97
EBIT Estimation
-1190.6
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15182
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading